Nascent Biotech Inc (OTCMKTS:NBIO) Stock Continues to Trend Lower
Clinical stage biotech firm Nascent Biotech Inc (OTCMKTS:NBIO) is mainly focused on the brain cancer space and yesterday it made an announcement with regards to a significant new milestone.
Trading Data
On Tuesday, NBIO stock decreased 4.51% to $0.0550 with 186.08K shares, compared to volume of 298.80K shares. The stock moved within a range of $0.0523 – 0.0576 after opening trade at $0.0530.
Nascent Submits Phase 2 Clinical Research Protocol to FDA for Review and Approval
The company announced yesterday that the protocol in relation to its Phase 2 clinical trials had been submitted to the United States Food and Drug Administration for approval and review. The approval and the review of the protocol are necessary for the company so as to commence the next stage of the development of the product Pritumumab. The data that had been collected from the Phase 1 clinical research to look into the safety and tolerance of the product among patients suffering from Primary and Metastatic Brain Cancers had also been submitted to the regulatory body.
Nascent Biotech noted that it expected the initial comments from the FDA with regards to the application within 30 days since the day of filing. The latest development is an important one for the company and one that is expected to be watched closely by both investors as well as analysts. It will be interesting to see if the latest news leads to a heightened interest in the stock or not.
